Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration ...

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential ...

We have developed a rapid and scalable approach using rapid-mixing techniques to generate homogeneous lipid nanoparticle (LNP) formulations of siRNA, triglycerides, and hydrophilic weak-base drugs.

As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities ...

The global lipid nanoparticles market is on the cusp of remarkable expansion, projected to grow at a CAGR of 14% through 2035, according to a recent industry analysis. Estimated to generate USD 1,144.

One of the unmet needs in this field is the lack of a robust, sensitive, and multiplexed method for EV mRNA profiling. We established a new protocol using the NanoString low RNA input nCounter assay ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

OSE Immunotherapeutics partners with Inside Therapeutics & MiNT Laboratory to develop mRNA therapeutics and accelerate nanodrug development: Nantes, France Saturday, May 24, 2025, ...

The mRNA platform market holds significant opportunities, driven by advancements in LNP delivery systems, codon optimization, and synthetic biology tools like CRISPR-Cas9. These innovations support ...

New Ventures BC announced that twelve alumni from its annual New Ventures BC (NVBC) Competition will be pitching at Web Summit Vancouver, taking place May 28-30. They'll be competing for a $10,000 ...